Promoter holding
64.27%
ZL
Zenotech Laboratories Limited - Due diligence report
A 360° intelligence report on Zenotech Laboratories: trust score, financial health, credit view, compliance, directors, growth and distress …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Zenotech Laboratories — 360° Intelligence Report
Generated from MCA filings & public records81/100
Trust Score
Low Risk
Zenotech Laboratories is assessed as Low Risk with a Trust Score of 81/100. Zenotech Laboratories is an active public limited indian non-government company incorporated in 1989, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 09 Aug 2026 from the latest processed filings. Zenotech Laboratories Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
81/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
78/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 1 open (6.00 cr) · 9 satisfied (64.71 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Andhra Pradesh State Financial Corporation | 2 | 48.0 cr |
| Hdfc Bank Limited | 1 | 48.0 cr |
| Yes Bank Limited | 1 | 48.0 cr |
| Indian Overseas Bank | 1 | 48.0 cr |
| Andhra Bank | 2 | 48.0 cr |
| Technology Development Board | 1 | 48.0 cr |
Compliance Score: 78/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
- Delayed payments to MSME suppliers disclosed (8 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RAKESHCHANDRA JAGDISHPRASAD SINHA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JIGNESH ANANTRAY GORADIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PREMAL HEMANT GANDHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ABDUL GAFOOR MOHAMMAD | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KACHAPPILLY VARGHESE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JAGRUTI PRASHANT SHETH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AZADAR HUSAIN ASGHAR MEHDI KHAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Kachappilly Varghese Poly | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Sachin Laxmanappa Gavandare | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Nikkhil Venilal Kothhari | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 10 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Sun Pharmaceutical Industries Limited
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 12 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Zenotech Inc. | Subsidiary Company | 74.00% |
| Sun Pharmaceutical Industries Limited | Holding Company | 74.00% |
| Zenotech Farmaceutica Do Brasil Ltda | Subsidiary Company | 74.00% |
| Zenotech Laboratories Nigeria Limited | Subsidiary Company | 74.00% |
Key managerial personnel: KACHAPPILLY VARGHESE (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 65
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 37+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Profit declined two years in a row.
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 10.12 Lakh.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence75/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment80/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 6.00 cr already registered.
- Compliance record supports lending.
Investor view76/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events23 Jan 2026
Director appointed
Nikkhil Venilal Kothhari (Director)
26 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
28 Jan 2025
Director appointed
PREMAL HEMANT GANDHI (Director)
07 Nov 2024
Director appointed
Sachin Laxmanappa Gavandare (Ceo)
01 Feb 2020
Director appointed
RAKESHCHANDRA JAGDISHPRASAD SINHA (Director)
Director appointed
JAGRUTI PRASHANT SHETH (Director)
31 Mar 2019
Share transfer (FY 2019)
2220.00000000 shares to JAGDISHKUMAR KANAIYALAL PATEL
Share transfer (FY 2019)
650.00000000 shares to JAGDISH KANAIYALAL PATEL
20 Nov 2017
Director ceased
DINESH KAPOOR
25 Jul 2017
Securities allotted
26603068 Equity Shares - 119.71 cr raised
31 Mar 2017
Share transfer (FY 2017)
1.00000000 shares to KHALLEL PASHA
Share transfer (FY 2017)
1.00000000 shares to NADEEM SHAIKH HAKEEM PASHA
Share transfer (FY 2017)
1.00000000 shares to ANUSHA
Share transfer (FY 2017)
1.00000000 shares to NAVEEN
10
Key Observations
Auto-generated from the data aboveRevenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
10 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
1 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Tellabs Chemicals Private Limited | U24297MH1995PTC085453 | Mumbai, Maharashtra, India |
| Lifecom Pharmaceuticals (India)) Private Limited | U24117MH2000PTC126563 | Mumbai, Maharashtra, India |
| Tenshi Pharmaceuticals Private Limited | U70200KA2016PTC200180 | Bangalore South, Karnataka, India |
| Polydrug Laboratories Private Limited | U24231MH2004PTC147729 | Lower Parel, Maharashtra, India |
| Edkem Pharmaceuticals Limited | U24230GJ2016PLC092826 | Ahmedabad, Gujarat, India |
| Sanjivani Biochem Private Limited | U33110GJ2004PTC045012 | Ahmedabad, Gujarat, India |
| Maya Biotech | U55101CH1998PTC021391 | Chandigarh, Chandigarh, India |
| Refractory Shapes Limited | L26921MH1996PLC096012 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Zenotech Laboratories before audits and certifications: compliance score 78/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Zenotech Laboratories: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Zenotech Laboratories - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 81/100, distress signals and MSME payment-delay disclosures - know whether Zenotech Laboratories pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Zenotech Laboratories - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Zenotech Laboratories an active company?
Zenotech Laboratories has MCA status “Active” with a compliance score of 78/100 (Low Risk).
Is Zenotech Laboratories financially healthy?
Zenotech Laboratories has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.
Should I do business with Zenotech Laboratories?
Its overall Trust Score is 81/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Zenotech Laboratories?
The ultimate holding entity is Sun Pharmaceutical Industries Limited. 10 active director(s) are on record.
Does Zenotech Laboratories have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 9 earlier charge(s) stand satisfied.
Is Zenotech Laboratories up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 78/100 (Low Risk).
Is it risky to lend to Zenotech Laboratories?
Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
